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The present study, a secondary analysis of published data (B. Hitsman et al., 1999), assessed (a) the 
influence of initial positive mood (PM) on smoking cessation and (b) whether smokers low in PM 
benefited from fluoxetine versus placebo for cessation. Euthymic adult smokers ( N  = 103) received 10 
weeks of cessation treatment. Analyses showed a Time X PM interaction, indicating that higher baseline 
PM predicted decreased abstinence during treatment but increased abstinence afterward, mediated by 
time to dropout. Dichotomous initial PM interacted with drug, suggesting a benefit of fluoxetine for 
low-PM smokers. Results indicate that lower pretreatment PM may inhibit long-term cessation. Smokers 
with lower baseline PM may benefit from treatment that increases PM. 
Keywords: positive affect, smoking cessation, fluoxetine, SSRI 
Cigarette smoking remains a major, preventable source of dis- 
ease and premature death in the United States and is associated 
with approximately 20% of all deaths (Centers for Disease Con- 
trol, 1999). Even though the negative health consequences of 
smoking are well established and widely known, nearly one in four 
American adults remains a regular smoker (Centers for Disease 
Control, 2002). Some evidence suggests that current smokers 
attempting to quit may actually be less likely to be successful than 
smokers of 20 years ago (Irvin & Brandon, 2000; h i n ,  Hendricks, 
& Brandon, 2003). Although this hardening hypothesis is not 
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uniformly accepted (Warner & Burns, 2003), its expression has 
prompted interest in identifying psychological and/or biological 
conditions that impede the ability of some continuing smokers to 
quit successfully (Gilbert & Gilbert, 1995; Gilbert, Gilbert, & 
Schulz, 1998). 
Research on psychiatric comorbidities hypothesized to inhibit 
smoking cessation has been focused chiefly on characteristics that 
are associated with negative mood. In comparison, relatively little 
work has examined the potential influence of positive mood on 
smoking behavior. Positive mood is conceptualized as a pleasant, 
animated mood state reflecting feelings of enthusiasm, elation, and 
peppiness (Watson & Tellegen, 1985). The lack of consideration 
of positive mood in the tobacco literature may reflect a view that 
positive and negative mood are at opposite ends of a single mood 
construct (e.g., Russell & Carroll, 1999), indicating that elevated 
positive mood is the equivalent of an absence of negative mood. 
However, evidence suggests that positive mood and negative mood 
are related but distinct constructs (Watson, Clark, & Tellegen, 
1988; Watson & Tellegen, 1999), with different biological bases 
(Davidson, 1992) and psychological correlates (Watson et al., 
1988). 
However, the tobacco literature has recently begun to reflect 
greater interest in the possible impact of positive mood on smoking 
behavior. This research suggests that low levels of positive mood 
may also play an important role in maintaining smoking and 
inhibiting cessation. For example, in a large-scale survey study, 
Presson, Chassin, and Sherman (2002) found that adults with low 
levels of positive mood were more likely to smoke than were their 
counterparts with higher levels of positive mood. Cook, Spring, 
McChargue, and Hedeker (2004) found that anhedonic smokers 
(i.e., those with chronically low positive mood) reported a greater 
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increase in craving during acute nicotine withdrawal than less 
anhedonic smokers did. Similarly, in a lab-based study, Zinser, 
Baker, Sherman, and Cannon (1992) found that, among continuing 
smokers, low levels of positive mood induced by stress predicted 
an increase in cigarette craving. In the same study, craving was 
associated with negative mood among withdrawing smokers but 
not among continuing smokers. Rabois and Haaga (2003) also 
reported that smokers who experienced decreased positive mood in 
response to a mood induction felt increased temptation to smoke. 
Further evidence relating low positive mood to urge to smoke is 
the finding that smokers who carry the variable number of tandem 
repeats polymorphism on the gene that encodes the dopamine-4 
receptor respond to smoking cues by exhibiting both dispropor- 
tionately heightened cigarette cravings and diminished positive 
mood (Hutchison, Lachance, Niaura, Bryan, & Smolen, 2002). 
To the extent that diminished positive mood after quitting smok- 
ing predicts decreased likelihood of abstinence (al'Absi, Hat- 
sukami, Davis, & Wittmer, 2004), a treatment that heightens 
positive mood could plausibly be expected to increase the proba- 
bility of abstinence. Indeed, Cook, Spring, McChargue, Borrelli, et 
al. (2004) found that the modestly effective cessation aid fluox- 
etine (Niaura et al., 2002) increased positive mood among smokers 
attempting to quit. Also, Shiffman et al. (2000) found that the 
first-line cessation treatment bupropion limited a postcessation 
reduction in positive mood, although a later study failed to repli- 
cate this finding (Lerman et al., 2002). 
These observed links among low positive mood, prominent 
cigarette craving, and smoking suggest that diminished positive 
mood could be an important impediment to smoking cessation. 
However, although a low level of positive mood during nicotine 
withdrawal has been associated with increased craving and poor 
cessation outcome, to our knowledge, the impact of having a low 
level of positive mood prior to cessation has not been assessed. 
The first aim of the current study is, therefore, to test the hypoth- 
esis that smokers with lower levels of positive mood at the outset 
of smoking cessation treatment are less likely to quit smoking than 
those with higher levels of positive mood. 
Additionally, because fluoxetine treatment during cessation ap- 
pears to curtail post-quit decrements in positive mood (Cook, 
Spring, McChargue, Borrelli, et al., 2004; Shiffman et al., 2000), 
it seems plausible that smokers with low levels of pre-quit positive 
mood might especially benefit from cessation treatment incorpo- 
rating fluoxetine pharmacotherapy. However, no published re- 
search has directly tested that hypothesis. The second aim of the 
current study is, therefore, to test the hypothesis that smokers with 
lower initial positive mood are more likely to quit successfully 
when receiving fluoxetine rather than placebo. 
Method 
Participants 
Participants were 103 regular smokers (59% female) who were admin- 
istered mood measures as part of a placebo-controlled, double-blind trial of 
fluoxetine as an aid for smoking cessation plus weight control. All were 
between the ages of 18 and 65 (M = 42.1, SD = 9.8); most were Caucasian 
(99%) and college educated (56.6%). All were enrolled in a smoking 
cessation plus weight gain prevention trial conducted in North Chicago 
(Hitsman et al., 1999), and approximately 47% (n = 49) also provided data 
for a multisite, industry-sponsored trial of fluoxetine for smoking cessation 
(Niaura et al., 2002) and comprised a portion of the samples described by 
Borrelli, Papandonatos, Spring, Hitsman, and Niaura (2004); Borrelli, 
Spring, Niaura, Hitsman, and Papandonatos (2001); Hitsman, Spring, Bor- 
relli, Niaura, and Papandonatos (2001); and Borrelli et al. (1999). The 
remainder (n = 54) were recruited to the North Chicago site after the 
multisite trial had concluded. 
At study entry, participants smoked an average of 28.5 cigarettes per day 
(SD = 10.3) and had a mean score of 7.0 (SD = 1.7) on the Fagerstrom 
Tolerance Questionnaire (FTQ; Fagerstrom, 1978). Exclusionary criteria 
were scores of 14 or higher on the Hamilton Depression Rating Scale 
(Endicott, Cohen, Nee, Fleiss, & Sarantakos, 1981; Hamilton, 1960), 
pregnancy, hypertension, current use of psychotropic medication, current 
psychiatric illness, current use of tobacco products other than cigarettes, 
current use of nicotine replacement products, recent major life event, 
suicidal ideation, and history of bipolar disorder. 
Procedure 
Following initial screening, participants underwent a physical examina- 
tion, medical history, chest X-ray, and blood testing (complete blood 
chemistry and differential). Participants were randomized on a double- 
blind basis to receive 9 weeks of 30 or 60 mg fluoxetine or placebo 
concurrent with 10 weekly sessions of individual, manualized cognitive- 
behavioral therapy for smoking cessation. Individual therapy sessions were 
intended to aid cessation by teaching coping skills, stimulus control tech- 
niques, and relapse prevention. Sessions lasted 60-90 min and were 
administered by doctoral-level therapists who participated in a standard- 
ized, prestudy training meeting. Treatment fidelity was ensured via pre- 
study training and a treatment manual. The treatment manual contained a 
checklist for each session and was completed by clinicians following each 
session. 
At Visit 2, participants began pharmacotherapy and selected a target quit 
date (TQD) within the subsequent 2 weeks. The latest possible TQD was 
24 hr prior to the Week 4 visit. Participants received medication (or 
placebo) for approximately 2 weeks prior to the TQD. Following the 
10-week treatment phase, participants attended four monthly follow-up 
visits, with the final visit occurring 26 weeks after the end of treatment, or 
32-34 weeks post-TQD (see Niaura et al., 2002, for additional protocol 
details). 
Measures 
Smoking status. We assessed smoking status by combining three sep- 
arate measures: self-reported smoking, expired air carbon monoxide (CO), 
and salivary cotinine, each of which we collected at the beginning of each 
treatment and follow-up visit. Participants who reported any smoking since 
the last visit, had CO values greater than eight parts per million, or had 
cotinine values greater than 20 ng/mL were classified as smokers at that 
visit. Smoking status was assessed over time, beginning at the fourth 
treatment visit (1-2 days post-TQD) through the final follow-up visit. 
Positive mood. Positive mood was assessed via the Vigor subscale of 
the Profile of Mood States (POMS; McNair, Lorr, & Droppleman, 1971). 
The Vigor subscale assesses moods such as jubilation, happiness, and 
peppiness, with scores ranging from 0 to 32. Participants completed the 
POMS once per day for 3 consecutive days prior to beginning treatment. 
The average of participants' Vigor scores across these 3 days was used as 
a measure of baseline positive mood. The POMS Vigor subscale exhibited 
adequate internal consistency at baseline in the current study (Cronbach's 
a = .88). It was chosen as the measure of positive affect in preference to 
alternative scales because it is the measure most frequently reported in the 
tobacco literature, particularly in the context of smoking cessation. The 
POMS Vigor subscale has been administered to measure acute effects of 
nicotine on positive mood and alertness (e.g., Gilbert, Dibb, Plath, & 
Hiyane, 2000; Griesar, Zajdel, & Oken, 2002; Levin et al., 1998; Spiga et 
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al., 1998) as well as to measure postcessation changes in positive mood 
(e.g., al'Absi et al., 2004; Cook, Spring, McChargue, & Hedeker, 2004; 
Jarvik et al., 2000; Patten, Martin, Calfas, Brown, & Schroeder, 2000). 
Nicotine dependence. We used the eight-item FTQ (Fagerstrom, 1978) 
to assess participants' degree of nicotine dependence. The FTQ consists of 
the sum of behavioral responses suggestive of nicotine dependence (e.g., 
smoking early in the morning, smoking many cigarettes per day). Scores 
range from 0 to 11, with values of 7 or greater suggesting nicotine 
dependence. 
Drug assignment. As part of the larger trial, all participants in the 
current study were randomized on a double-blind basis to one of three 
pharmacotherapy conditions: placebo (n = 34). 30 mg fluoxetine (n = 30), 
or 60 mg fluoxetine (n = 39). In the current study, all participants were 
coded as having received either placebo (n = 34) or fluoxetine (n = 69), 
after it was determined that no significant differences existed between the 
30-mg and 60-mg groups on a variety of variables (combined fluoxetine 
and norfluoxetine blood levels, nicotine dependence, baseline vigor, base- 
line negative affect, smoking status over time, age, gender, and post-TQD 
symptoms of withdrawal). 
Time to dropout. Participants were considered to have dropped out of 
the study when they stopped attending either treatment or follow-up 
sessions. Time to dropout was coded as the number of weeks between the 
first treatment visit and the last visit attended. 
Analytic Plan 
The analyses tested the hypothesis that lower levels of baseline positive 
mood would be associated with a reduced likelihood of abstinence. The 
primary outcome measure was the dichotomous variable bioverified smok- 
ing status measured over the course of 10 visits (from Week 1 through 9 
months post-TQD). We coded participants as abstinent (0) or smoking (1) 
at each visit. We performed longitudinal analysis of smoking status over 
the 10 time points using a logistic regression model for correlated dichot- 
omous outcomes, estimated using the generalized estimating equations 
(GEE) method (Liang & Zeger, 1986), implemented via SAS PROC 
GENMOD. We adopted an intent-to-treat approach. For participants with 
missing smoking status data, we performed no manual imputations (i.e., we 
treated missing as missing rather than assuming overdeterministically that 
missing was equal to smoking). It is important to note that GEE places no 
restrictions on the number of observations included per individual, so that 
participants with missing smoking status data were not excluded from the 
analysis. Instead, we estimated model parameters using all available data- 
the combined available smoking status data from all randomized 
participants. 
The GEE model characterized the repeated dichotomous classifications 
(abstinent vs. smoking) in terms of initial cessation and time-related 
changes in cessation. We initially included both time and time squared 
terms in all analyses to assess for both linear and quadratic time trends. We 
included nicotine dependence, gender, and drug assignment as covariates 
in all analyses. Controlling for these covariates, we conducted specific tests 
to estimate the effect of baseline positive mood on initial smoking status 
and time-related changes in the effect of baseline positive mood on smok- 
ing status over time (Baseline Positive Mood X Time and Baseline Positive 
Mood X Time Squared interactions). We removed nonsignificant terms 
from the model in a backward manner (i.e., Baseline Positive Mood X 
Time Squared first, then Baseline Positive Mood X Time) and refit the 
model. The GEE model provides statistical tests that are robust to the 
misspecification of the dependency structure that may result from repeated 
assessments of individuals over time (Diggle, Liang, & Zeger, 1994). In the 
current analysis, we chose an m-dependent (or Toeplitz) correlation struc- 




As shown in Table 1, we tested baseline demographic and 
smoking history variables to determine whether they were signif- 
icantly associated with either baseline positive mood or drug 
assignment. Baseline positive mood was not associated with drug 
assignment, gender, age, cigarettes smoked per day, or nicotine 
dependence. We found no significant differences between drug 
groups on gender, age, cigarettes smoked per day, or nicotine 
dependence. 
Primary Analyses 
Table 2 presents the results of the GEE analysis testing the 
effects of baseline positive mood and time on smoking status over 
10 time points (Visits 4 through 9 and four follow-up visits). We 
included gender, nicotine dependence, and drug assignment in the 
model as covariates. Nicotine dependence was the only covariate 
that significantly predicted smoking over time, such that partici- 
pants with higher FTQ scores at baseline were more likely to 
continue smoking than those with lower nicotine dependence 
scores. Although baseline positive mood was not significantly 
associated with smoking status on quit day (Visit 4), there was a 
significant linear interaction between baseline positive mood and 
time (z = -2.45, p = .014). To determine the direction of this 
interaction, we performed a median split on baseline positive mood 
and plotted abstinence rates of the two baseline positive mood 
groups (low and high) over time (see Figure 1). As the figure 
shows, the linear Baseline Positive Mood X Time interaction 
indicates that, initially, from Session 4 (the latest possible quit day) 
through Visit 7, participants with lower baseline positive mood 
were more likely to be abstinent. However, this trend reversed 
subsequently such that participants with lower baseline positive 
mood were less likely to be abstinent from Visit 8 through Visit 13 
(32 weeks after quit date). 
Mediational Analyses 
We then conducted a series of post hoc mediational analyses to 
explore factors that might explain the association between baseline 
positive mood and smoking status over time. In testing for medi- 
Table 1 
Means and Standard Deviations for Baseline Smoking and 
Demographic Variables by Drug Assignment 
All 
Placebo Fluoxetine participants 
(n = 34)" (n = 69)b (N = 103)' 
Variable M SD M SD M SD 
Age (years) 44.9 10.5 40.7 9.3 42.1 9.8 
Baseline positive mood 14.4 4.9 13.4 5.7 13.7 5.5 
FTQ 7.2 1.7 6.9 1.7 7.0 1.7 
Cigaretteslday 28.6 7.9 28.5 11.4 28.5 10.3 
Weeks to dropout 12.5 7.3 13.4 7.8 13.1 7.6 
Note. FTQ = Fagerstrom Tolerance Questionnaire. 
" 18 women, 16 men. 43 women, 26 men. ' 61 women, 42 men. 
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Table 2 
Generalized Estimating Equations Model Predicting Smoking 
Status Over Time 
Variable Estimate SE Z score 
Covariates 
Gender -0.321 0.740 -0.43 
Nicotine dependence -0.484 0.180 -2.70** 
Drug -0.385 0.218 -1.77 
Time effects 
Time 0.356 0.064 5.56** 
Time X Time -0.009 0.002 -4.06** 
F'rimary effects 
Baseline positive mood 0.045 0.041 1.09 
Baseline Positive Mood X Time -0.007 0.003 -2.45* 
Nore. Smoking status was coded as 0 (abstinent) or 1 (smoking). 
* p  < .05. * * p  < .01. 
ation, we used the approach recommended by Cohen and Cohen 
(1983). With this approach, mediation requires that a series of four 
steps be satisfied. First, the independent variable (IV) must signif- 
icantly predict the dependent variable (DV) when the mediator is 
excluded from the model. Second, when the mediating variable is 
added to the model described in Step 1, the effect of the IV on the 
DV must be weakened. Third, the mediating variable must be a 
significant predictor of the DV when the IV is excluded from the 
model. Fourth, when the IV is added to the model described in 
Step 3, the effect of the mediator on the DV must be weakened. 
We tested several variables as potential mediators explaining the 
changing relationship between positive mood and smoking status 
over time. We chose candidate variables previously shown to be 
predictive of smoking status, including self-efficacy (Borrelli & 
Mermelstein, 1994), nicotine withdrawal symptoms (Piasecki, 
Jorenby, Smith, Fiore, & Baker, 2003a, 2003b), negative mood 
(Kenford et al., 2002), and reasons for smoking (Schneider, 1984). 
We also tested changes in positive mood over time and time to 
dropout as potential mediators. 
Analyses indicated that time to dropout was the only significant 
mediator of the changing association between baseline positive 
mood and smoking status over time. As shown in Table 2, when 
time to dropout was not included in the model, Baseline Positive 
Mood X Linear Time was a significant predictor of smoking status 
over time (z = -2.45, p = .014). However, when time to dropout 
was included in the model (see Table 3), the Baseline Positive 
Mood X Linear Time term became nonsignificant (z = -0.44, 
p = .331). When Baseline Positive Mood X Linear Time was 
excluded from the model, time to dropout was a significant pre- 
dictor of smoking status over time (z = -5.04, p = ,0001). 
Specifically, participants who dropped out earlier were more likely 
than others to have been smoking prior to dropping out. When 
Baseline Positive Mood X Linear Time was included in the model, 
the effect of time to dropout became nonsignificant (z = - 1.76, 
p = ,079). In other words, in both cases, when the second variable 
was added to the model, the effect of the first variable on the DV 
became nonsignificant, indicating that time to dropout fully me- 
diated the association between baseline positive mood and smok- 
ing status over time. In sum, these findings indicate a significant 
effect of baseline positive mood on the slope representing change 
in smoking status over time. This effect was explained by time to 
dropout, which was inversely related to baseline positive mood 
(Pearson r = -.21, p = .038), indicating that smokers with higher 
levels of baseline positive mood were more likely to drop out of 
the study at an earlier stage. 
Interaction With Drug Assignment 
When we refitted the GEE model of smoking over time, includ- 
ing Baseline Positive Mood X Drug Assignment as a predictor, the 
interaction term was only a marginally significant predictor of 
smoking status ( z  = 1.55, p = .11). However, plots comparing 
those above and below the median on baseline positive mood for 
abstinence rates on placebo versus fluoxetine (see Figure 2) sug- 
gested an interaction that the current study was not sufficiently 
powered to detect. Consequently, we refitted the GEE model of 
smoking over time after recoding participants as either high or low 
- - -D - - High PM 
Weeks After TQD 
Figure I .  Percentage abstinence over time for smokers who scored above or below the median on baseline 
positive mood (PM; available data). TQD = target quit date. 
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Table 3 
Generalized Estimating Equations Mediational Model Predicting 
Smoking Status Over Time 







Time X Time 
Primary effects 
Baseline positive mood 
Baseline Positive Mood 
Mediator 
Weeks to dropout 
0.024 
X Time -0.001 
Note. Smoking status was coded as 0 (abstinent) or 1 (smoking). 
* p  < .05. * * p  < .01. 
in baseline positive mood on the basis of the median split. The 
median score for baseline positive mood in the current sample was 
14. As is shown in Table 4, there was a significant interaction 
between drug assignment and dichotomous baseline positive mood 
( z  = 2.31, p = .021). 
To determine the direction of the interaction, we stratified the 
data on the basis of the median split of baseline positive mood and 
used GEE to test the effect of drug assignment for each group 
separately. Among the low baseline positive mood group, there 
was a significant effect of drug (z = -3.32, p = .001), indicating 
that those treated with fluoxetine were more likely to be abstinent 
than those treated with placebo. For those with high baseline 
positive mood, the effect of drug was not significant ( z  = 0.82, p = 
.410). That is, fluoxetine had no influence on abstinence for 
participants who exhibited higher positive mood at study entry, but 
those with lower levels of baseline positive mood were signifi- 
cantly more likely to quit smoking on fluoxetine compared with 
placebo. Medication status was not associated with change in 
positive mood over time during treatment, t(3,476) = -0.44, p = 
,657. Similarly, the interaction between baseline positive mood 
and medication status was not a significant predictor of change in 
positive mood over time, t(3, 476) = - 1.47, p = ,142. 
Discussion 
The current study tests the hypothesis that low baseline positive 
mood negatively predicts smoking cessation in a trial of fluoxetine 
as an adjunct to cognitive-behavioral therapy. To our knowledge, 
this is the first study to directly test the influence of baseline 
positive mood on smoking cessation. Results show a significant 
effect of baseline positive mood on change in smoking status over 
time. At the outset of treatment, participants with higher levels of 
baseline positive mood showed a reduced likelihood of being 
abstinent. However, by the end of treatment this relationship 
reversed, such that throughout follow-up higher levels of baseline 
positive mood were associated with increased probability of ab- 
stinence. The relationship between baseline positive mood and 
change in smoking status over time was mediated by time to 
dropout, which was inversely related to baseline positive mood. 
Smokers with higher levels of baseline positive mood were more 
likely to drop out of the study at an earlier stage, but if they did not 
drop out they were more likely to be abstinent at end of follow-up. 
We also found an interaction between dichotomous baseline pos- 
itive mood and drug assignment. That is, smokers with low initial 
positive mood were more likely to be abstinent if treated with 
fluoxetine than placebo. Among those who had higher positive 
mood at baseline, fluoxetine had no effect on abstinence. 
Surprisingly, we found that either high or low positive mood at 
baseline could be detrimental to cessation. Participants with 
heightened positive mood at baseline tended to drop out of treat- 
ment earlier than others. In the long run, though, as Figure 1 
indicates, individuals with higher positive mood who remained in 
treatment were more successful at maintaining abstinence than 
participants who entered treatment with lower positive mood. We 
were unable to uncover an explanation for the heightened dropout 
of those who entered treatment with elevated baseline positive 
mood. For example, heightened dropout was not associated with 
greater nicotine dependence or withdrawal, number of previous 
quit attempts, medication side effects, or fluoxetine metabolite 
levels. 
One speculative explanation for the association between base- 
line positive mood and time to dropout is that those with higher 
positive mood at baseline might have been overconfident about 
their ability to quit successfully. Perhaps these participants had 
unrealistic expectations about the easiness of quitting or about the 
efficacy of the medication. Subsequently, they might have felt 
discouraged at finding cessation difficult and therefore terminated 
treatment early. In a similar vein, Haaga and Stewart (1992) found 
that quitting smokers with moderate levels of self-efficacy for 
preventing a cessation lapse from becoming a relapse were more 
likely to be abstinent 1 year later than those with high or low 
self-efficacy. That is, those who were the most confident about 
their ability to prevent relapse did better than those with very little 
confidence but somewhat (nonsignificantly) less well than those 
with moderate confidence. In the current study we did not assess 
specific self-efficacy about not letting a lapse turn into a relapse. 
General self-efficacy was not significantly related to either base- 
line positive mood or time to dropout in the current study. How- 
ever, general self-efficacy may be a poor proxy for more specific 
self-efficacy or confidence about the ability to quit smoking. 
The present study is the first to suggest that smokers with low 
levels of pre-quit positive mood may benefit from cessation treat- 
ment that includes antidepressant pharmacotherapy. It is unclear 
by what mechanism fluoxetine aided cessation for smokers with 
low baseline positive mood. Although previous research has indi- 
cated that fluoxetine reduces post-quit decrements in positive 
mood (Cook, Spring, McChargue, Borrelli, et al., 2004), we found 
no effect of drug on change in positive mood over time. Prior 
findings have shown that low positive mood is associated with 
heightened cravings to smoke cigarettes (Cook, Spring, McChar- 
gue, & Hedeker, 2004; Rabois & Haaga, 2003), which could 
undermine successful cessation. Although an effect on craving 
might plausibly have explained fluoxetine's beneficial effect on 
abstinence for low positive affect smokers, the effect of drug on 
craving over time was not significant in the current study. One 
potential explanation for the lack of association between drug and 
smoking status among smokers with high baseline positive mood 
is that they were adversely affected by fluoxetine treatment in 
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Low Positive Mood 
I - - - c - - placebo -+- fluoxetine I 
4 5 6 7 8 9 10  11  12 13  
Weeks After TQD 
High Positive Mood 
- . -c - - placebo e f l u o x e t i n e  
1 0  
0 1 , I I I t 
4 5 6 7 8 9 10  11 12 13  
Weeks After TQD 
Figure 2. Percentage abstinence over time by baseline positive mood and by drug assignment. TQD = target 
quit date. 
some way, although not in such a manner as to cause earlier 
dropout. Regression analyses indicated that individuals at varying 
levels of baseline positive mood did not drop out differentially in 
response to receiving drug or placebo. Alternatively, for partici- 
pants with high baseline positive mood, fluoxetine may simply 
have had little incremental therapeutic value when added to 
cognitive-behavioral cessation treatment. 
Generalizability of the current findings may be limited to those 
who share certain characteristics of the sample, such as their high 
motivation to quit smoking and the absence of comorbid physio- 
logical and psychiatric conditions. Also, it is unknown whether 
initial positive mood or fluoxetine would influence cessation in the 
same manner among smokers attempting to quit on their own 
without the assistance of a formal treatment program. Further 
research is needed to increase our understanding of the relationship 
between positive mood and smoking cessation. Researchers should 
explore the possibility that higher levels of positive mood are 
linked to increased attrition and should test potential mechanisms. 
Additional research is also needed to confirm or refute the present 
finding that smokers with low levels of positive mood derive a 
disproportionate cessation benefit from fluoxetine. 
The current findings suggest that not only negative moods but 
also deficient positive moods play a role in nicotine dependence. 
Reports that low positive mood is linked to increased cigarette 
cravings during nicotine deprivation (e.g., Cook, Spring, Mc- 
Chargue, & Hedeker, 2004; Rabois & Haaga, 2003; Zinser et al., 
1992) suggest that low positive mood may be implicated indirectly 
in cessation failure. Low positive mood during deprivation has 
been linked directly to cessation failure (al'Absi et al., 2004). 
Finally, given that low positive mood is a hallmark symptom of 
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Table 4 
Generalized Estimating Equations Model Predicting Smoking 








Time X Time 
Primary effects 
Baseline positive mood 
Drug 
Baseline Positive Mood X Drug 
Estimate SE Z score 
Note. Smoking status was coded as 0 (abstinent) or 1 (smoking). 
* p  < .05. * * p  < .01. 
depression (Clark & Watson, 1991; Coyne, 1994) and that depres- 
sive symptoms predict cessation failure (Covey, Glassman, & 
Stetner, 1990; Hughes, 1992; Kenford et al., 2002), it is not 
surprising that low positive mood is associated with diminished 
abstinence. In the current study, fluoxetine promoted abstinence 
among those with low baseline positive mood, although it did not 
prevent a reduction in positive mood after participants quit 
smoking. 
From a clinical standpoint, these findings suggest a need for 
smoking cessation treatments to begin to address deficient positive 
mood in addition to excessive negative mood. At present, behav- 
ioral cessation treatments that include a mood management com- 
ponent tend to emphasize self-regulation of negative moods. It 
may be as important for treatments to begin to incorporate tech- 
niques that could help smokers overcome initially diminished 
hedonic capacity or further decrements in positive mood that occur 
after smoking has been discontinued. 
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